What is Viveve?
Founded in 2005, Viveve Medical, Inc. operates as a specialized medical device manufacturer dedicated to advancing women's health through technological innovation. The company focuses on the development and commercialization of non-invasive treatments designed to improve quality of life for patients suffering from intimate health conditions. By integrating advanced medical engineering with a deep understanding of patient-centric care, Viveve has established a distinct market position as a provider of high-impact, specialized healthcare solutions.
The company's operational strategy centers on the rigorous validation of its medical technologies, ensuring that its product portfolio meets the highest standards of clinical efficacy. As a key player in the medtech space, Viveve continues to bridge the gap between complex medical science and accessible, patient-focused therapeutic outcomes.
How much funding has Viveve raised?
Viveve has raised a total of $210.8M across 21 funding rounds:
Debt
$500K
Share Placement
$6M
Share Placement
$12M
Share Placement
$6M
Stock Offering
$15.5M
Debt
$10M
Stock Offering
$31.7M
Debt
$30M
Stock Offering
$32.4M
Stock Offering
$18.8M
Stock Offering
$6.8M
Stock Offering
$11.5M
Multiple Rounds
$7.6M
Debt (2014): $500K, investors not publicly disclosed
Share Placement (2014): $6M supported by 5AM Ventures, Alta BioEquities, and GBS Venture Partners
Share Placement (2015): $12M featuring Alta Bioequities, 5AM Ventures, and Stonepine Capital
Share Placement (2015): $6M backed by RTW Investments, Manchester Management Company, Wexford Capital LP, Alta Bioequities, and Stonepine Capital
Stock Issuance/Offering (2016): $15.5M, investors not publicly disclosed
Debt (2016): $10M led by Bridge Bank
Stock Issuance/Offering (2017): $31.7M, investors not publicly disclosed
Debt (2017): $30M featuring CRG LP
Stock Issuance/Offering (2018): $32.4M, investors not publicly disclosed
Stock Issuance/Offering (2018): $18.8M, investors not publicly disclosed
Stock Issuance/Offering (2019): $6.8M, investors not publicly disclosed
Stock Issuance/Offering (2019): $11.5M, investors not publicly disclosed
Debt (2020): $1M featuring PPP
Other Financing Round (2020): $3M, investors not publicly disclosed
Other Financing Round (2020): $3.6M, investors not publicly disclosed
Key Investors in Viveve
5AM Ventures
Five AM Ventures is a life science focused venture capital firm that backs early stage biotech and health care innovators, partnering closely with founders to shape companies, fund rigorous science and help bring new therapies and technologies to patients.
CRG LP
CR Group L.P. (CRG) is a global investment firm focused on enhancing healthcare through flexible growth capital solutions, specializing in credit and select equity investments across life sciences and healthcare services.
RTW Investments
RTW is a life sciences investment and innovation firm that focuses on biotech and medtech innovation throughout the entire lifecycle, providing both capital and scientific expertise to support transformative companies.
What's next for Viveve?
Looking ahead, Viveve is positioned to leverage its recent capital infusion to accelerate the commercial expansion of its core product lines. The strategic focus will likely remain on deepening market penetration and exploring new clinical applications for its non-invasive technology platform. Given the company's history of securing institutional support from specialized life science investors, the path forward involves balancing aggressive growth with the maintenance of its high-quality clinical standards.
The firm's ability to attract consistent financing suggests a robust outlook for its future development, particularly as it continues to navigate the evolving regulatory and competitive landscape of the global women's health market. Continued investment in research and strategic partnerships will be essential for Viveve to sustain its competitive advantage and drive long-term value for its stakeholders.
